Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Download PDF
Dtsch Med Wochenschr 2007; 132(49): 2650-2653
DOI: 10.1055/s-2007-993115
DOI: 10.1055/s-2007-993115
Konsensus | Review article
Kardiologie, Diabetologie© Georg Thieme Verlag KG Stuttgart · New York
Positionsbestimmung zum Stellenwert von Pioglitazon in der Diabetestherapie
Significance of pioglitazone in the therapy of diabetes: determining the current positionFurther Information
Publication History
Publication Date:
29 November 2007 (online)
Schlüsselwörter
Diabetes mellitus Typ 2 - Glitazone - kardiovaskuläres Risiko - Pioglitazon - Rosiglitazon
Key words
type 2 diabetes mellitus - pioglitazone - rosiglitazone - cardiovascular risk - thiazolidinediones
Literatur
- 1
Ahmed W, Ziouzenkova O, Brown J. et al .
PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?.
J Intern Med.
2007;
262
(2)
184-198
MissingFormLabel
- 2
Berhanu P, Kipnes M S, Khan M A. et al .
Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2
diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing
stable statin therapy.
Diab Vasc Dis Res.
2006;
3
(1)
39-44
MissingFormLabel
- 3
Chappuis B, Braun M, Stettler C. et al .
Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial
glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective,
randomized crossover study.
Diabetes Metab Res Rev.
2007;
23
(5)
392-399
MissingFormLabel
- 4
Chiquette E, Ramirez G, Defronzo R.
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk
factors.
Arch Intern Med.
2004;
164
(19)
2097-2104
MissingFormLabel
- 5
Deeg M A, Buse J B, Goldberg R B. et al .
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle
concentrations and sizes in patients with type 2 diabetes and dyslipidemia.
Diabetes Care.
2007;
30
(10)
2458-2464
MissingFormLabel
- 6
Derosa G, D’Angelo A, Ragonesi P D. et al .
Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular
risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
J Clin Pharm Ther.
2006;
31
(4)
375-383
MissingFormLabel
- 7
Dormandy J A, Charbonnel B, Eckland D J. et al .
Secondary prevention of macrovascular events in patients with type 2 diabetes in the
PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):
a randomised controlled trial.
Lancet.
2005;
366
(9493)
1279-1289
MissingFormLabel
- 8
Erdmann E, Charbonnel B, Wilcox R G. et al .
Pioglitazone Use and Heart Failure in Patients with Type 2 Diabetes and Preexisting
Cardiovascular Disease: Data from the PROactive Study (PROactive 08).
Diabetes Care.
2007;
30
(11)
2773-2778
MissingFormLabel
- 9
Erdmann E, Dormandy J A, Charbonnel B. et al .
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with
type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive
05) Study.
J Am Coll Cardiol.
2007;
49
(17)
1772-1780
MissingFormLabel
- 10
Erdmann E, Schneider C A, Yates J.
Effects of pioglitazone in patients with type 2 diabetes and reduced glomerular filtration
rate: an analysis from PROactive.
Diabetes.
2007;
56
(Suppl 1)
A 178
MissingFormLabel
- 11 European Medicines Agency confirms positive benefit-risk balance for rosiglitazone
and pioglitazone. http://www.emea.europa.eu/pdfs/human/press/pr/48427707en.pdf
MissingFormLabel
- 12 Fachinformation actos®. Stand August 2007
MissingFormLabel
- 13 Fachinformation Avandia®. Stand Januar 2007
MissingFormLabel
- 14
Forst T, Pfützner A, Lübben G. et al .
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion,
adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the
PIOSTAT Study.
Metabolism.
2007;
56
(4)
491-496
MissingFormLabel
- 15 GlaxoSmithKline (GSK) .Clinical trial observation of an increased incidence of fractures in female patients
who received long-term treatment with Avandia (rosiglitazone maleate) tablets for
type 2 diabetes mellitus (Letter to Health Care Providers). February 2007 Available from www.fda.gov/MedWatch/safety/2007/Avandia_GSK_Ltr.pdf
MissingFormLabel
- 16
Goldberg R B, Kendall D M, Deeg M A. et al .
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients
with type 2 diabetes and dyslipidemia.
Diabetes Care.
2005;
28
(7)
1547-1554
MissingFormLabel
- 17
Goodman S B, Jiranek W, Petrow E, Yasko A W.
The effects of medications on bone.
J Am Acad Orthop Surg.
2007;
15
(8)
450-460
MissingFormLabel
- 18
Home P D, Pocock S J, Beck-Nielsen H. et al .
Rosiglitazone evaluated for cardiovascular outcomes.
N Engl J Med.
2007;
357
(1)
28-38
MissingFormLabel
- 19
Hsiao A, Worrall D S, Olefsky J M, Subramaniam S.
Variance-modeled posterior inference of microarray data: detecting gene-expression
changes in 3T3-L1 adipocytes.
Bioinformatics.
2004;
20
(17)
3108-3127
MissingFormLabel
- 20
Kahn S E, Haffner S M, Heise M A. et al .
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
N Engl J Med.
2006;
355
(23)
2427-2443
MissingFormLabel
- 21
Krauss R M.
Lipids and lipoproteins in patients with type 2 diabetes.
Diabetes Care.
2004;
27
(6)
1496-1504
MissingFormLabel
- 22
Lago R M, Singh P P, Nesto R W.
Congestive heart failure and cardiovascular death in patients with prediabetes and
type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
Lancet.
2007;
370
(9593)
1129-1136
MissingFormLabel
- 23
Lincoff A M, Wolski K, Nicholls S J, Nissen S E.
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus:
a meta-analysis of randomized trials.
JAMA.
2007;
298
(10)
1180-1188
MissingFormLabel
- 24 Mele K D. Avandia® (rosiglitazone maleate) GlaxoSmithKline NDA 21 - 071 Supplement 022 FDA META-ANALYSIS. http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4308s1-00-index.htm
MissingFormLabel
- 25
Nissen S E, Wolski K.
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular
causes.
N Engl J Med.
2007;
356
(24)
2457-2471
MissingFormLabel
- 26
Reynolds K, Goldberg R B.
Thiazolidinediones: beyond glycemic control.
Treat Endocrinol.
2006;
5
(1)
25-36
MissingFormLabel
- 27
Singh S, Loke Y K, Furberg C D.
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
JAMA.
2007;
298
(10)
1189-1195
MissingFormLabel
- 28
Wilcox R, Bousser M G, Betteridge D J. et al .
Effects of pioglitazone in patients with type 2 diabetes with or without previous
stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular
Events 04).
Stroke.
2007;
38
(3)
865-873
MissingFormLabel
- 29
Yang Y X, Lewis J D, Epstein S, Metz D C.
Long-term proton pump inhibitor therapy and risk of hip fracture.
JAMA.
2006;
296
2947-2953
MissingFormLabel
- 30 FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes Drug Avandia. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01743.html
MissingFormLabel
Prof. Dr. Erland Erdmann
Klinikum der Universität zu Köln, Klinik III für Innere Medizin
Kerpener Str. 62
50924 Köln
Email: erland.erdmann@uni-koeln.de